Identification

Name
Dinutuximab
Accession Number
DB09077
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

Protein chemical formula
C6422H9982N1722O2008S48
Protein average weight
145000.0 Da
Sequences
Not Available
Synonyms
  • Dinutuximab beta
  • Monoclonal antibody ch14.18
External IDs
APN-311 / APN311 / ch14.18 / ch14.18-UTC
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
UnituxinInjection3.5 mg/mLIntravenousUnited Therapeutics2015-03-10Not applicableUs
Categories
UNII
7SQY4ZUD30
CAS number
1363687-32-4

Pharmacology

Indication

Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

Structured Indications
Pharmacodynamics

In vitro dinutuximab binds to neuroblastoma tumour cells and mediates the lysis of tumour cells via cell-mediated and complement-mediated cytotoxicity.

Mechanism of action

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour.

TargetActionsOrganism
AGanglioside GD2
inhibitor
Human
Absorption
Not Available
Volume of distribution

The mean volume of distribution at steady state (Vdss) is 5.4 L

Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

The terminal half-life is 10 days

Clearance

The clearance is 0.21 L/day and increases with body size

Toxicity

The most common (incidence 15 %) grade 3 or 4 treatment-related adverse events in dinutuximab compared with standard therapy recipients were neuropathic pain (52 vs. 6 %), fever without neutropenia (39 vs. 6 %), any in-fection (39 vs. 22 %), hypokalaemia (35 vs. 2 %), hypersensitivity reactions (25 vs. 1 %), hyponatraemia (23 vs. 4 %), elevation of alanine transferase levels (23 vs. 3 %) and hypotension (18 vs. 0 %). Based on its mechanism of action, dinutuximab may cause fetal harm when administered to a pregnant woman however, there are no studies in pregnant women and no reproductive studies in animals to inform the drug-associated risk. Non-clinical studies suggest that dinutuximab-induced neuropathic pain is mediated by binding of the antibody to the GD2 antigen located on the surface of peripheral nerve fibers and myelin and subsequent induction of cell- and complement-mediated cytotoxicity. In clinical trials, 114 (85%) patients treated in the dinutuximab/RA group experienced pain despite preĀ­-treatment with analgesics including morphine sulfate infusion. Severe (Grade 3) pain occurred in 68 (51%) patients in the dinutuximab/RA group compared to 5 (5%) patients in the RA group. Pain typically occurred during the dinutuximab infusion and was most commonly reported as abdominal pain, generalized pain, extremity pain, back pain, neuralgia, musculoskeletal chest pain, and arthralgia.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Dinutuximab.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Dinutuximab.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Dinutuximab.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dinutuximab.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Dinutuximab.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Dinutuximab.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dinutuximab.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dinutuximab.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Dinutuximab.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Dinutuximab.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Dinutuximab.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Dinutuximab.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dinutuximab.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Dinutuximab.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Dinutuximab.Experimental
BarbitalBarbital may increase the hypotensive activities of Dinutuximab.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Dinutuximab.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dinutuximab.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Belimumab.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dinutuximab.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dinutuximab.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Dinutuximab.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dinutuximab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Dinutuximab.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dinutuximab.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Dinutuximab.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Dinutuximab.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dinutuximab.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dinutuximab.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dinutuximab.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dinutuximab.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dinutuximab.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Dinutuximab.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Dinutuximab.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Dinutuximab.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dinutuximab.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dinutuximab.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dinutuximab.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Dinutuximab.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Dinutuximab.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dinutuximab.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dinutuximab.Approved
ClozapineThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Dinutuximab.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dinutuximab.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dinutuximab.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Dinutuximab.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dinutuximab.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dinutuximab.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dinutuximab.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dinutuximab.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Dinutuximab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Dinutuximab.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dinutuximab.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dinutuximab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.Approved, Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.Approved
DuloxetineDinutuximab may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dinutuximab.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dinutuximab.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dinutuximab.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dinutuximab.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Dinutuximab.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dinutuximab.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Dinutuximab.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Dinutuximab.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Dinutuximab.Approved, Investigational
FingolimodDinutuximab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Dinutuximab.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Dinutuximab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Dinutuximab.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Dinutuximab.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dinutuximab.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dinutuximab.Approved, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dinutuximab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dinutuximab.Approved, Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Dinutuximab.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dinutuximab.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dinutuximab.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dinutuximab.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Dinutuximab.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Dinutuximab.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dinutuximab.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Dinutuximab.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Dinutuximab.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Dinutuximab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Dinutuximab.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dinutuximab.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dinutuximab.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dinutuximab.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dinutuximab.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dinutuximab.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Dinutuximab.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dinutuximab.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dinutuximab.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Dinutuximab.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Dinutuximab.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dinutuximab.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dinutuximab.Approved, Investigational
LevodopaDinutuximab may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Dinutuximab.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Dinutuximab.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Dinutuximab.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dinutuximab.Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dinutuximab.Approved
MethohexitalMethohexital may increase the hypotensive activities of Dinutuximab.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dinutuximab.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dinutuximab.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Dinutuximab.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dinutuximab.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dinutuximab.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dinutuximab.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Dinutuximab.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dinutuximab.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Dinutuximab.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Dinutuximab.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Dinutuximab.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dinutuximab.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Dinutuximab.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dinutuximab.Approved
NicorandilNicorandil may increase the hypotensive activities of Dinutuximab.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dinutuximab.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Dinutuximab.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dinutuximab.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dinutuximab.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dinutuximab.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dinutuximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dinutuximab.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Dinutuximab.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dinutuximab.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Dinutuximab.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dinutuximab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dinutuximab.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Dinutuximab.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Dinutuximab.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Dinutuximab.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dinutuximab.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Dinutuximab.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dinutuximab.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Dinutuximab.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dinutuximab.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Dinutuximab.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dinutuximab.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Dinutuximab.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dinutuximab.Approved
PrimidonePrimidone may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dinutuximab.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Dinutuximab.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Dinutuximab.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dinutuximab.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dinutuximab.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dinutuximab.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dinutuximab.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dinutuximab.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dinutuximab.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Dinutuximab.Approved
RisperidoneDinutuximab may increase the hypotensive activities of Risperidone.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Dinutuximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Dinutuximab.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dinutuximab.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Dinutuximab.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Dinutuximab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Dinutuximab.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Dinutuximab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Dinutuximab.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dinutuximab.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dinutuximab.Approved, Vet Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dinutuximab.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Dinutuximab.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Dinutuximab.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dinutuximab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Dinutuximab.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Dinutuximab.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dinutuximab.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dinutuximab.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Dinutuximab.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Dinutuximab.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dinutuximab.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dinutuximab.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Dinutuximab.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dinutuximab.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Dinutuximab.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dinutuximab.Approved, Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Dinutuximab.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.Approved
TofacitinibDinutuximab may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Dinutuximab.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dinutuximab.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dinutuximab.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dinutuximab.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dinutuximab.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Dinutuximab.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dinutuximab.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Dinutuximab.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Dinutuximab.Approved
Food Interactions
Not Available

References

General References
  1. Dhillon S: Dinutuximab: first global approval. Drugs. 2015 May;75(8):923-7. doi: 10.1007/s40265-015-0399-5. [PubMed:25940913]
  2. Ahmed M, Cheung NK: Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014 Jan 21;588(2):288-97. doi: 10.1016/j.febslet.2013.11.030. Epub 2013 Dec 1. [PubMed:24295643]
  3. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991 Jan 1;51(1):144-9. [PubMed:1988079]
  4. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R, Furukawa K: Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem. 2005 Aug 19;280(33):29828-36. Epub 2005 May 26. [PubMed:15923178]
External Links
KEGG Drug
D10559
PubChem Substance
347910402
ChEMBL
CHEMBL3137342
Drugs.com
Drugs.com Drug Page
Wikipedia
Dinutuximab
ATC Codes
L01XC16 — Dinutuximab
FDA label
Download (446 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDisseminated Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma1
1Not Yet RecruitingTreatmentNeuroblastomas2
1SuspendedTreatmentRecurrent Neuroblastoma / Refractory Neuroblastoma / Stage 4 Neuroblastoma1
1, 2CompletedTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentEffects of Immunotherapy / Neoplasm, Residual / Neuroblastomas1
2Active Not RecruitingTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2RecruitingTreatmentMetastatic Malignant Neoplasm in the Lung / Metastatic Osteosarcoma / Recurrent Osteosarcoma1
2RecruitingTreatmentNeuroblastomas2
2TerminatedTreatmentNeuroblastomas1
2Unknown StatusTreatmentNeuroblastoma Recurrent1
2, 3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3CompletedTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3Unknown StatusTreatmentNeuroblastomas1
Not AvailableTerminatedNot AvailableNeuroblastomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionIntravenous3.5 mg/mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20140170155No2014-02-182038-02-18Us

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991 Jan 1;51(1):144-9. [PubMed:1988079]

Drug created on June 18, 2015 11:47 / Updated on November 06, 2017 06:46